Qiagen (QGEN) reported $501.87 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 5.5%. EPS of $0.57 for the same period compares to $0.52 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $490.53 million, representing a surprise of +2.31%. The company delivered an EPS surprise of +5.56%, with the consensus EPS estimate being $0.54.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Qiagen (QGEN) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.52 per share when it actually produced earnings of $0.55, delivering a surprise of 5.77%.Over the last four quarters, the c ...

文章核心观点 - 美国FDA批准了QIAGEN公司的QIAstat-Dx Meningitis/Encephalitis Panel用于临床使用,这是QIAGEN公司在2024年获得的第四个FDA批准的QIAstat-Dx检测项目 [1][3] - 细菌性脑膜炎病例在美国已达到2014年以来的最高水平,但许多医疗机构仍依赖传统的微生物检测方法,这种方法需要24小时以上的培养时间,而QIAstat-Dx只需约1小时即可出结果 [2] - QIAstat-Dx Meningitis/Encephalitis Panel可同时检测导致社区获得性脑膜炎/脑炎的多种病原体,并提供循环阈值(Ct)值和扩增曲线等临床信息,为医生提供更全面的诊断依据 [3][4] 公司概况 - QIAGEN是全球领先的"样本到洞见"解决方案提供商,为客户提供从样本采集到分子洞见的全套解决方案 [6] - 截至2024年6月30日,QIAGEN在全球拥有超过5,900名员工,分布在35个国家和地区 [7] 行业动态 - 细菌性脑膜炎病例在美国达到近年来最高水平,但许多医疗机构仍依赖传统的微生物检测方法 [2] - 快速准确的诊断对于脑膜炎/脑炎这种危急病症至关重要,QIAstat-Dx系统可以在1小时内提供结果,满足临床需求 [3]

Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper respiratory infections in outpatient settings ...

文章核心观点 - 公司将于2024年11月6日发布第三季度财报 [1] - 公司将于2024年11月7日举行财报电话会议 [1] - 公司是全球领先的样本到洞见解决方案提供商,为客户提供从样本到分子洞见的全套解决方案 [2] 公司概况 - 公司总部位于荷兰文洛,是一家跨国控股公司 [2] - 公司为超过50万客户提供分子诊断(人类健康)和生命科学(学术、制药研发和工业应用,主要为法医)领域的解决方案 [2] - 截至2024年6月30日,公司在全球35个国家拥有超过5,900名员工 [2]

QIAGEN N.V. (QGEN) is well-poised to grow in the coming quarter, driven by its strategic alliances with researchers and pharma companies. The company's expansive next-generation sequencing (NSG) portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to currency fluctuations, which can adversely affect its financial results. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) stock has risen 6% compared with 4% growth ...

Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation (IVDR). This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement underscores QIAGEN's commitment to meeti ...

QIAGEN N.V.(QGEN) and Becton, Dickinson and Company or BD's (BDX) joint venture, PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set. PAXgene will be used for reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). QIAGEN will commercialize the newly launched set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolati ...

QIAGEN N.V. (QGEN) recently announced that Bode Technology will be the exclusive global commercial partner for its GEDmatch PRO genealogy database. QIAGEN's subsidiary Verogen inked the deal with Bode. The company has been providing GEDmatch PRO to customers since the acquisition of its subsidiary, Verogen, in early 2023. The latest partnership is aimed at accelerating the use of QIAGEN's next-generation sequencing (NGS) products in human identification (HID) and forensic investigations. QGEN's Likely Stock ...

Venlo, the Netherlands, and Germantown, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data. The multi-year agreement between QIAGEN's sub ...